株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

体外癌診断市場:世界の市場規模、戦略、予測 (2016年〜2020年)

In Vitro Cancer Diagnostics Markets: Global Market Size, Strategies and Forecasts 2016 to 2020 including Screening Market Sizing

発行 Howe Sound Research 商品コード 350276
出版日 ページ情報 英文 222 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
体外癌診断市場:世界の市場規模、戦略、予測 (2016年〜2020年) In Vitro Cancer Diagnostics Markets: Global Market Size, Strategies and Forecasts 2016 to 2020 including Screening Market Sizing
出版日: 2016年01月12日 ページ情報: 英文 222 Pages
概要

当レポートでは、世界の体外癌診断市場について調査分析し、15ヶ国・4地域における肺癌、乳癌、大腸癌、前立腺癌、その他の癌を対象に、市場規模、戦略、予測など、体系的な情報を提供しています。

第1章 イントロダクションと市場の定義

第2章 市場概要

  • 市場参入企業
  • バイオプシーで特定される病気
  • バイオプシー部位
  • バイオプシー材料の分析
  • 癌の兆候:リキッドバイオプシー技術
  • 癌治療プロトコルの変化
  • 産業構造
  • 主要なリキッドバイオプシー企業のプロファイル

第3章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 検査装置と自動化
  • 診断技術の発展

第4章 リキッドバイオプシーの最近の発展

  • 最近の発展
  • Illuminaが新会社GRAILを設立:バイオプシーによる癌の早期発見を可能
  • ASCO:リキッドバイオプシーにおける進歩、進行中の課題、など

第5章 国別市場規模:北米

  • 米国
    • 肺癌検査
    • 乳癌検査
    • 大腸癌検査
    • 前立腺癌検査
    • その他の癌検査
    • リキッドバイオプシー全体
  • カナダ
    • 肺癌検査
    • 乳癌検査
    • 大腸癌検査
    • 前立腺癌検査
    • その他の癌検査
    • リキッドバイオプシー全体

第6章 国別市場:欧州

  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • ロシア
  • その他

第7章 国別市場:アジア太平洋地域

  • 中国
  • 日本
  • 韓国
  • インド
  • オーストラリア
  • その他

第8章 国別市場:ラテンアメリカ、アフリカ・中東

  • ブラジル
  • メキシコ
  • その他
  • アフリカ・中東

第9章 世界市場サマリー

  • 世界

第10章 潜在的な市場機会の規模

  • 癌スクリーニング (国別) :肺癌、乳癌、大腸癌
  • 癌スクリーニング (国別) :前立腺癌、その他の癌、すべての癌
  • 潜在的な市場規模:癌診断
  • 潜在的な市場規模:癌管理

付録

図表

目次

The Diagnostic, Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity?

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Introduction and Market Definition

  • 1.1 What is Liquid Biopsy?
  • 1.2 The Genetics Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size.
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 Liquid Biopsy and Clinical Laboratory Testing - Spending Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. Market Overview

  • 2.1 Market Participants
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Genomic Instrumentation Supplier
    • 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4 Pharmaceutical/Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab.
    • 2.1.8 Physician Lab
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Conditions Identified with Biopsies
    • 2.2.1 Cancer
    • 2.2.2 Precancerous conditions
    • 2.2.3 Inflammatory condiditons
  • 2.3 Biopsy Sites
  • 2.4 Analysis of Biopsied Material
  • 2.5 Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1 Liquid Biopsy Technology Overview
    • 2.5.2 Circulating Tumor Cells
      • 2.5.2.1 Types of CTCs
      • 2.5.2.2 CellSearch Detection Method
      • 2.5.2.3 Epic Sciences Detection Method
      • 2.5.2.4 Maintrac Detection Method
      • 2.5.2.5 Other Methods
    • 2.5.3 Circulating Tumor DNA
    • 2.5.4 Exosomes and Micro Vesicles
  • 2.6 Changing the Cancer Treatment Protocol
    • 2.6.1 Issues and Limitations to Liquid Biopsy Adoption
    • 2.6.2 The Cancer Screening Market Opportunity
      • 2.6.2.1 GRAIL - Exploiting the Screening Opportunity
    • 2.6.3 Cancer Management
      • 2.6.3.1 Risk Assessment Role In Cancer Management
      • 2.6.3.2 Therapy Assessment Role In Cancer Management
      • 2.6.3.3 Disease Monitoring Role In Cancer Management
    • 2.6.4 Phases of Adoption - Outlook for Usage
    • 2.6.5 The Promise of Liquid Biopsy
  • 2.7 Industry Structure
    • 2.7.1 Hospital Testing Share
    • 2.7.2 Economies of Scale
      • 2.7.2.1 Hospital vs. Central Lab
    • 2.7.3 Physician Office Lab's
    • 2.7.4 Physician's and POCT
  • 2.8 Profiles of Key Liquid Biopsy Companies
    • 2.8.1 AdnaGen (now Qiagen)
    • 2.8.2 Agena Bioscience
    • 2.8.3 Angle plc
    • 2.8.4 ApoCell
    • 2.8.5 Biocept
    • 2.8.6 BioFluidica
    • 2.8.7 Bio-Rad Laboratories
    • 2.8.8 Boreal Genomics
    • 2.8.10 Chronix Biomedical
    • 2.8.11 Clearbridge BioMedics
    • 2.8.12 Cynvenio
    • 2.8.13 Cytolumina Technologies Corp.
    • 2.8.14 CytoTrack
    • 2.8.15 Diagnologix LLC
    • 2.8.16 Epic Sciences
    • 2.8.17 Exosome Diagnostics
    • 2.8.18 Exosome Sciences
    • 2.8.19 Fluidigm Corp
    • 2.8.20 Fluxion Biosciences
    • 2.8.21 Genomic Health
    • 2.8.39 GRAIL
    • 2.8.22 Guardant Health
    • 2.8.23 HansaBiomed
    • 2.8.23 Horizon Discovery
    • 2.8.24 iCellate
    • 2.8.25 Illumina
    • 2.8.26 Inivata
    • 2.8.27 Janssen Diagnostics
    • 2.8.28 Molecular MD
    • 2.8.29 Myriad Genetics
    • 2.8.30 Natera
    • 2.8.31 New Oncology
    • 2.8.32 Personal Genome Diagnostics
    • 2.8.33 RainDance Technologies
    • 2.8.34 Rarecells SAS
    • 2.8.35 Silicon Biosystems
    • 2.8.36 Sysmex Inostics
    • 2.8.37 SRI International
    • 2.8.38 Trovagene

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Non Invasive Game Changer
    • 3.1.2 Lower Cost
    • 3.1.3 Greater Accuracy.
    • 3.1.4 Wide Range of Potential Uses
    • 3.1.5 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 Lower prices
    • 3.2.2 Lack of Standards.
    • 3.2.3 Protocol Resistance.
    • 3.2.4 Initial Adoption Has No Cost Savings
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • 4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy
  • 4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy
  • 4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
  • 4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen
  • 4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test
  • 4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options
  • 4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab
  • 4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance
  • 4.10 Biocept Q1 Revenues Rise With Test Volume Growth
  • 4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers
  • 4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood
  • 4.13 Cynvenio to present new clinical data
  • 4.14 EKF, Angle Collaborate for Liquid Biopsy Development
  • 4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer
  • 4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen
  • 4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics
  • 4.18 Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.19 Agena Bioscience Launches Smaller Format MassArray
  • 4.20 Personal Genome Diagnostics Aims for FDA Clearance
  • 4.21 HTG Molecular Diagnostics Files for IPO of up to $60M
  • 4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
  • 4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs
  • 4.24 Inivata Raises $6.6M to Develop ctDNA Assays
  • 4.25 Epic Sciences Raises $30M in Private Financing
  • 4.26 New Release in Line of Liquid Biopsy CLIA Tests
  • 4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test
  • 4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field
  • 4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test
  • 4.29 DNA in blood can track cancer development, response in real time

5. Country Market Sizes - North America

  • 5.1 United States of America
    • 5.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 5.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 5.2 Canada
    • 5.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 5.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1 France
    • 6.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.2 Germany
    • 6.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.3 United Kingdom
    • 6.3.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.3.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.3.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.4 Spain
    • 6.4.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.4.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.4.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.5 Italy
    • 6.5.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.5.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.5.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.5.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.5.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.5.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.6 Russia
    • 6.6.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.6.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.6.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.6.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.6.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.6.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.7 Remainder of Europe and Former Soviet Union
    • 6.7.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.7.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.7.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.7.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.7.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.7.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.3.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.3.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.4.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.4.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.5.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.5.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.5.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.5.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.5.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.6.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.6.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.6.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.6.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.6.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1 Brazil
    • 8.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.2 Mexico
    • 8.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.3 Rest of Latin America
    • 8.3.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.3.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.3.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.4 Africa and The Middle East
    • 8.4.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.4.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.4.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1 Global
    • 9.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 9.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 9.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 9.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 9.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 9.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

10. Potential Market Opportunity Sizes

  • 10.1 Cancer Screening by Country: Lung, Breast & Colorectal
  • 10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 10.3 Potential Market Size - Cancer Diagnosis
  • 10.4 Potential Market Size - Cancer Management

Appendices

  • I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Biopsy Sites
  • Table 4 Advantages of Liquid Biopsy in Screening Market
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 10 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 11 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 12 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 13 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 14 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 15 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 16 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 17 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 18 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 19 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 20 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 21 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 22 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 23 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 24 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 25 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 26 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 27 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 28 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 29 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 30 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 31 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 32 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 33 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 34 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 35 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 36 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 37 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 38 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 39 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 40 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 41 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 42 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 43 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 44 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 45 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 46 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 47 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 48 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 49 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 50 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 51 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 52 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 53 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 54 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 55 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 56 All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 57 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 58 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 59 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 60 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 61 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 62 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 63 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 64 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 65 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 66 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 67 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 68 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 69 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 70 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 71 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 72 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 73 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 74 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 75 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 76 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 77 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 78 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 79 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 80 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 81 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 82 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 83 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 84 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 85 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 86 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 87 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 88 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 89 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 90 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 91 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 92 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 93 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 94 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 95 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 96 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 97 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 98 All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 99 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 100 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 101 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 102 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 103 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 104 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 105 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 106 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 107 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 108 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 109 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 110 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 111 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 112 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 113 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 114 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 115 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 116 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 117 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 118 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 119 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 120 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 121 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 122 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 123 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 124 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 125 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 126 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 127 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 128 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 129 Potential Screening Market: Lung, Breast & Colorectal
  • Table 130 Potential Screening Market: Prostate, Other & All
  • Table 131 Potential Cancer Diagnosis Market Size.
  • Table 132 Potential Cancer Management Market Size
  • Table 133 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2 Comparison of Liquid Biopsy Classes
  • Figure 3 Characteristics of Different Vesicle Types
  • Figure 4 Percentage of World Population Over 65
Back to Top